Literature DB >> 18679062

Changes in gene expression of gastric mucosa during therapeutic acid inhibition.

Kristin G Nørsett1, Astrid Laegreid, Waclaw Kusnierczyk, Mette Langaas, Sonja Ylving, Reidar Fossmark, Simen Myhre, Sture Falkmer, Helge L Waldum, Arne K Sandvik.   

Abstract

BACKGROUND: Long-term therapy with potent acid inhibitors is a common treatment for gastro-esophageal reflux disease. Administration of proton pump inhibitors (PPIs) causes profound and continuous hypochlorhydria by inhibition of the proton pump in gastric parietal cells. Long-term hypergastrinaemia increases mucosal thickness and enterochromaffin-like cell density in oxyntic mucosa.
OBJECTIVE: The aim of this study was to see whether this very common clinical intervention induces significant changes in the gastric mucosal gene expression pattern.
METHODS: Seven patients suffering from gastro-esophageal reflux disease were included in this study. Endoscopic biopsies were taken from the corpus mucosa before and toward the end of a 3-month treatment with the PPI esomeprazole.
RESULTS: Microarray analysis identified 186 differentially expressed genes. A high proportion of genes with changed gene expression levels during PPI treatment are involved in proliferation, apoptosis, and stress response.
CONCLUSION: This study identified many genes that were not previously known to be affected by inhibition of gastric acid secretion. Further characterization of the functional roles of genes whose expression is modulated by potent acid inhibition may give new insight into the biological responses to potent acid inhibition, including the mucosal response to the moderately increased gastrin levels encountered in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679062     DOI: 10.1097/MEG.0b013e3282f5dc19

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

Authors:  Kristin G Nørsett; Islay Steele; Cedric Duval; Stephen J Sammut; Senthil V M Murugesan; Susan Kenny; Lucille Rainbow; Rod Dimaline; Graham J Dockray; D Mark Pritchard; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-30       Impact factor: 4.052

2.  Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.

Authors:  Giovanni Gori; Giacomo Spinelli; Claudio Spinelli; Marco Tuccori; Corrado Blandizzi; Mario Del Tacca
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

Review 3.  Novel roles of gastrin.

Authors:  Rod Dimaline; Andrea Varro
Journal:  J Physiol       Date:  2014-03-24       Impact factor: 5.182

Review 4.  The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity.

Authors:  Edward S Bliss; Eliza Whiteside
Journal:  Front Physiol       Date:  2018-07-12       Impact factor: 4.566

5.  Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways.

Authors:  Wei Xie; Xielin Huang; Renpin Chen; Ruru Chen; Tang Li; Wei Wu; Zhiming Huang
Journal:  Drug Des Devel Ther       Date:  2019-08-22       Impact factor: 4.162

6.  NR4A2 is regulated by gastrin and influences cellular responses of gastric adenocarcinoma cells.

Authors:  Kristine Misund; Linn-Karina Myrland Selvik; Shalini Rao; Kristin Nørsett; Ingunn Bakke; Arne K Sandvik; Astrid Lægreid; Torunn Bruland; Wenche S Prestvik; Liv Thommesen
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

7.  Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus.

Authors:  Yoomi Lee; Aleksandra M Urbanska; Yoku Hayakawa; Hongshan Wang; Andrew S Au; Aesis M Luna; Wenju Chang; Guangchun Jin; Govind Bhagat; Julian A Abrams; Richard A Friedman; Andrea Varro; Kenneth K Wang; Malcolm Boyce; Anil K Rustgi; Antonia R Sepulveda; Michael Quante; Timothy C Wang
Journal:  Oncotarget       Date:  2017-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.